Chromosome

Volastra Therapeutics Announces First Patient Dosed in Phase Ib Clinical Trial of Sovilnesib

Retrieved on: 
Martedì, Aprile 16, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Chromosome, Fast Track, Ovarian cancer, Food, Clinical research, Gynecologic Oncology (journal), Therapy, Dana–Farber Cancer Institute, Microsoft, Patient, MPH, Medicine, FRCP, Associate, Division, Pharmaceutical industry

Volastra Therapeutics , a clinical-stage biotechnology company, today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC).

Key Points: 
  • Volastra Therapeutics , a clinical-stage biotechnology company, today announced it has dosed the first patient in its Phase Ib clinical trial evaluating sovilnesib in patients with platinum-resistant or refractory high-grade serous ovarian cancer (HGSOC).
  • This trial ( NCT06084416 ) is a randomized dose optimization study of once-daily oral sovilnesib at different dose levels to establish the recommended Phase 2 dose.
  • The company is also progressing its internally developed KIF18A inhibitor, VLS-1488, in an ongoing Phase 1 clinical trial ( NCT05902988 ).
  • “Advancing our two chemically differentiated KIF18A inhibitors in parallel Phase 1 clinical trials presents the rare opportunity to efficiently gather comparative clinical data,” said Charles Hugh-Jones, M.D., FRCP, Chief Executive Officer at Volastra.

Agilent Receives European IVDR Class C Certification for GenetiSure Dx Postnatal Assay

Retrieved on: 
Lunedì, Aprile 15, 2024
Science, Other Science, Research, Oncology, Health, Medical Devices, Health Technology, Genetics, DSM-IV codes, Cytogenetics, Agilent Technologies, Safety, Certification, Birth, Pregnancy, Edible frog, Patient, Genome, Intellectual disability, European, Chromosome, IVDR, Comparative genomic hybridization, COVID-19, Medical device

Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification.

Key Points: 
  • Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification.
  • This certification demonstrates that the assay meets the higher standards established by IVDR.
  • “The GenetiSure Dx Postnatal Assay will advance the postnatal diagnosis of chromosomal abnormalities, as it combines high resolution, accuracy, and speed in a single test.
  • With the European IVDR Class C Certification, we are confident that this assay will continue to serve the needs of healthcare professionals and their patients across the EU.”
    Jenipher Dalton, chief quality and regulatory officer at Agilent, summarized the announcement’s significance.

Trilogene Seeds Releases First Triploid Cannabis Seed Line

Retrieved on: 
Giovedì, Aprile 18, 2024
Multimedia, THCA, Cannabis, Gene, Seed, GMO, Research, Risk, Chromosome, Growth, Plant, Agriculture

CHICAGO, April 18, 2024 /PRNewswire/ -- Trilogene Seeds, renowned for their cutting-edge cannabis genetics and breeding techniques, unveiled their new line of triploid THCa seeds, a significant breakthrough in cannabis cultivation.

Key Points: 
  • CHICAGO, April 18, 2024 /PRNewswire/ -- Trilogene Seeds, renowned for their cutting-edge cannabis genetics and breeding techniques, unveiled their new line of triploid THCa seeds, a significant breakthrough in cannabis cultivation.
  • The introduction of triploid genetics in cannabis, a concept previously applied to other agricultural crops like seedless watermelons, affords benefits for indoor and outdoor growers, extractors, and consumers.
  • Triploids, with an additional set of chromosomes, are essentially sterile, channeling energy towards more desirable traits rather than seed development.
  • "We take an approach that prioritizes integrity and rigorous scientific validation, pushing forward innovation within the cannabis industry," said Matthew Haddad, CEO and Founder of Trilogene Seeds.

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Retrieved on: 
Martedì, Aprile 2, 2024
Press club, B cell, Longevity, TELO, Chromosome, Research, DNA, MD, Skin, Osteoarthritis, Blood, Ageing, Pharmaceutical industry

BALTIMORE, April 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that anti-aging expert and New York Times bestselling author Michael F. Roizen, MD, will present promising pre-clinical research on Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024. Dr. Roizen serves as Telomir’s special advisor on age reversal.

Key Points: 
  • Dr. Roizen serves as Telomir’s special advisor on age reversal.
  • The search for treatments to combat the diseases of aging has increasingly become the focus of many medical professionals and, more recently, society in general.
  • “Our event at the National Press Club will provide us with an opportunity to share Telomir-1’s potential with the public on a national stage,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir Pharmaceuticals.
  • As Telomir continues to uncover new and promising data through our pre-clinical work, we remain committed to sharing our data publicly.

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Retrieved on: 
Martedì, Aprile 9, 2024
Eurostat, Diagnosis, Civil service commission, Speech, X chromosome, Brain, Medicine, MECP2, Disease, Laxative, Seizure, Nervous system, Patient, Chromosome, Committee, Knowledge, Constipation, Regulation, EMA, IRIS, Rett syndrome, Male, Intellectual disability, Clinical trial, European, COMP, Safety, European Commission, Marketing, Parent, Syndrome, DSM-IV codes, Anatomical pathology, Pharmaceutical industry

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Key Points: 


Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Retrieved on: 
Venerdì, Marzo 22, 2024
B cell, Conference, Longevity, National University Health System, TELO, The New York Times, BGCT, Health, Chromosome, Research, DNA, EDT, Laboratory, MD, Skin, Poster, Telomere, Osteoarthritis, Blood, NUHS, Ageing, Pharmaceutical industry

BALTIMORE, March 22, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and Danielle R. Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.

Key Points: 
  • The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.
  • This presentation builds on the data that was presented at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 in February.
  • “Presenting our poster at the Global Longevity Federation conference offers a significant opportunity for our team to showcase the potential for Telomir-1.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer

Retrieved on: 
Martedì, Marzo 26, 2024
Software, Research, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, Microsoft, Chromosome, Microsoft Research, Survival, Patient, Biomarker, Nature, Cancer, AI, CIN, Human, Medicine, MBA, FRCP, Therapy, CRISPR, Collaboration, Medical imaging

Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.

Key Points: 
  • Volastra leads the field in development of therapeutics that target chromosomal instability (CIN), a key characteristic of cancer associated with accelerated disease progression, increased resistance to therapies, and shortened patient survival.
  • While CIN is a hallmark of cancer, levels of CIN vary widely across tumor types from being nearly ubiquitous in some to only partially present in others.
  • Volastra’s two KIF18A inhibitors are in parallel Phase 1 clinical trials treating tumor types with near-universally high levels of CIN.
  • We are excited to apply our proprietary precision medicine platform to clinical trials in the rapidly advancing field of KIF18A inhibition.”

Function Oncology Announces Innovative Precision Medicine Partnership with Volastra Therapeutics

Retrieved on: 
Martedì, Marzo 26, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Genetics, Partnership, CIN, Medicine, Function, Chromosome, Patient, Neoplasm, Cancer, Disease, CRISPR, Medical imaging

Function Oncology , a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovative research and development partnership with Volastra Therapeutics , a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability (CIN).

Key Points: 
  • Function Oncology , a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovative research and development partnership with Volastra Therapeutics , a company pioneering novel approaches to treating cancer by targeting a tumor vulnerability known as chromosomal instability (CIN).
  • Function is leveraging its CRISPR-enabled platform to understand disease in unprecedented and patient-specific detail.
  • By moving beyond traditional gene sequencing to measuring gene function, the Volastra and Function teams aim to identify which patients would benefit from treatment with Volastra’s KIF18A inhibitors.
  • CRISPR technology has transformed precision medicine, and we are excited by the potential of Function’s innovative platform to expand the pool of patients that will benefit from KIF18A inhibitors.”

Genomenon Presents Study Identifying 11,000 Gene Disease Relationships Across the Clinical Exome at the ACMG Annual Clinical Genetics Meeting

Retrieved on: 
Giovedì, Marzo 14, 2024
Diagnosis, ANN, Gene, Comparison, Broad Institute, Genetic testing, Disease, Risk, CALM3, Patient, Chromosome, Virginia High School League, Doctor of Philosophy, NIH, Medicine, Genome, VUS, PLA2G6, Literature, ACMG, Data, CALM, Vaccine

ANN ARBOR, Mich., March 14, 2024 /PRNewswire-PRWeb/ -- Genomenon, a leading genomic intelligence company, presented data at the ACMG Annual Clinical Genetics Meeting today demonstrating how computational indexing of millions of published abstracts and full-text references combined with a systematic literature review can be used to rapidly and accurately characterize gene-disease relationships (GDRs) and to resolve variants of uncertain significance (VUS). The study was completed in less than six months and identified 10,745 germline GDRs and 5,973 germline GDRs with positive associations between a disease and gene. Each GDR is accompanied by well-documented scientific evidence curated by Genomenon's team of genetic scientists. Today's presentation shares a milestone in the company's mission to curate the human genome and understand the pathogenicity of any variant for patient diagnosis and precision medicine development.

Key Points: 
  • The study was completed in less than six months and identified 10,745 germline GDRs and 5,973 germline GDRs with positive associations between a disease and gene.
  • This need is underscored by the fact that the number of VUS's is growing exponentially due to increased genetic testing and sequencing.
  • The study used a literature-based approach that     gathered variants through Genomenon's Mastermind Genomic Intelligence Platform and variant databases.
  • The study demonstrated that there is only a 27% match of genetic variants listed in current databases and those found in the literature.

Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements

Retrieved on: 
Mercoledì, Marzo 6, 2024
Engineering, Doctor of Philosophy, CAR7, Research and development, Chromosome, Kite Pharma, CD7, Cell, Risk, MicroRNA, Safety, History, Malignancy, Patient, Development, Partnership, Vaccine

“miCAR7 is the product of thoughtful design and remarkable engineering,” commented Dr. Marco Alessandrini, PhD, Chief Executive Officer of Antion.

Key Points: 
  • “miCAR7 is the product of thoughtful design and remarkable engineering,” commented Dr. Marco Alessandrini, PhD, Chief Executive Officer of Antion.
  • Proof-of-Concept data for miCAR7 was unveiled for the first time at the 7th CAR-TCR Summit in London on February 28th, 2024.
  • In August of 2023, Antion successfully delivered novel gene constructs and a supporting data package for silencing of four relevant targets to Allogene.
  • With a validated technology platform, established operations and a history of fruitful collaboration, Antion is optimally positioned to accelerate its pipeline developments, while leveraging the full potential of its technology through key strategic partnerships with global innovation leaders.